AACR 2018: Boosting T-Cell Memory May Result in Longer-Lasting Responses in Patients Treated With Checkpoint Blockade Immunotherapies

Karma Oncology had a great time at AACR 2018 in Chicago where we covered everything from cancer immunotherapy treatments to cancer patient care to networking. One of the hot topics was how to get a longer lasting response from treatments such as checkpoint inhibitors. Here is a link to one of the interesting articles in The ASCO Post. 


On 20-04-2018 0 1408

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.


Make an appointment and we’ll contact you.